Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.
A short instructional video that demonstrates how to prepare and deliver Cosentyx injections.
Do not share links to this website or screenshots with patients, as this Novartis Healthcare Professional website is intended for healthcare professionals only.
If you do wish to share the injection video with patients, please share this link:
Click here for Cosentyx (secukinumab) prescribing information
CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate.
